The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Evonik invests in start-up to improve patient recovery after open-chest surgery
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Subscribe To Our Newsletter & Stay Updated
